| Year |
Citation |
Score |
| 2018 |
Basu H, Wilganowski N, Lieblich J, Wu G, Fokt I, Ramachandran S, Yu J, Titus M, Priebe W, Beebe DJ, Wilding G. Abstract B091: Small-molecule inhibitors targeting a specific metabolic pathway for precision therapy of advanced castrate-resistant prostate cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-B091 |
0.374 |
|
| 2018 |
Basu HS, Wilgonowski NL, Lieblich JL, Wu GT, Fokt I, Ramachandran S, Yu J, Titus M, Priebe W, Beebe DJ, Wilding G. Abstract 3846: A metabolic pathway targeted inhibitor for precision therapy of castrate-resistant prostate cancer Cancer Research. 78: 3846-3846. DOI: 10.1158/1538-7445.Am2018-3846 |
0.34 |
|
| 2017 |
Wong YN, Manola J, Hudes GR, Roth BJ, Moul JW, Barsevick AM, Scher RM, Volk MJ, Vaughn DJ, Williams SD, Fisch MJ, Cella D, Carducci MA, Wilding G. Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial. Clinical Genitourinary Cancer. PMID 29173976 DOI: 10.1016/J.Clgc.2017.10.001 |
0.481 |
|
| 2017 |
Engle JA, Traynor AM, Campbell TC, Wisinski KB, LoConte N, Liu G, Wilding G, Kolesar JM. Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 1078155217704989. PMID 28457192 DOI: 10.1177/1078155217704989 |
0.311 |
|
| 2016 |
Mahalingam D, Wilding G, Denmeade S, Sarantopoulas J, Cosgrove D, Cetnar J, Azad N, Bruce J, Kurman M, Allgood VE, Carducci M. Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours. British Journal of Cancer. 114: 986-94. PMID 27115568 DOI: 10.1038/Bjc.2016.72 |
0.378 |
|
| 2016 |
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England). PMID 26969090 DOI: 10.1016/S0140-6736(16)00559-6 |
0.336 |
|
| 2016 |
Kyriakopoulos CE, Heath EI, Eickhoff JC, Kolesar J, Yayehyirad M, Moll T, Wilding G, Liu G. A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer. Investigational New Drugs. PMID 26924129 DOI: 10.1007/S10637-016-0334-Y |
0.472 |
|
| 2016 |
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, ... ... Wilding G, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26903579 DOI: 10.1200/Jco.2015.64.2702 |
0.456 |
|
| 2016 |
Yu J, Weichmann AM, Craig A, Huang W, Church DR, Mehraein F, Parker LL, Beebe DJ, Wilding G, Basu HS. Abstract 4968: “Moonlighting Functions” of glycolytic enzymes relate to human prostate cancer invasion Cancer Research. 76: 4968-4968. DOI: 10.1158/1538-7445.Am2016-4968 |
0.392 |
|
| 2016 |
Carles J, Davis I, Bono JSd, Fizazi K, Gerritsen W, Rathkopf DE, Ryan CJ, Saad F, Steuber T, Wilding G, Park YC, Charnas R, Porre PD, Poppel HV. Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA + P) for ≥ 4 years (yrs) Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw372.24 |
0.307 |
|
| 2015 |
Deming DA, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Eickhoff JC, Kolesar JM, Fioravanti S, Greten TF, Compton K, Doyle AG, Wilding G, Duffy A, Liu G. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer : For submission to Investigational New Drugs. Investigational New Drugs. PMID 26666244 DOI: 10.1007/S10637-015-0314-7 |
0.318 |
|
| 2015 |
Carducci MA, Manola J, Nair SG, Liu G, Rousey S, Dutcher JP, Wilding G. Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800). Clinical Genitourinary Cancer. PMID 26272427 DOI: 10.1016/J.Clgc.2015.07.002 |
0.387 |
|
| 2015 |
Huang SX, Yun BS, Ma M, Basu HS, Church DR, Ingenhorst G, Huang Y, Yang D, Lohman JR, Tang GL, Ju J, Liu T, Wilding G, Shen B. Leinamycin E1 acting as an anticancer prodrug activated by reactive oxygen species. Proceedings of the National Academy of Sciences of the United States of America. 112: 8278-83. PMID 26056295 DOI: 10.1073/Pnas.1506761112 |
0.312 |
|
| 2015 |
Wisinski KB, Cantu CA, Eickhoff J, Osterby K, Tevaarwerk AJ, Heideman J, Liu G, Wilding G, Johnston S, Kolesar JM. Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials. American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 72: 958-65. PMID 25987691 DOI: 10.2146/Ajhp140591 |
0.301 |
|
| 2015 |
Haas N, Manola J, Ky B, Flaherty KT, Uzzo RG, Kane C, Jewett MA, Wood L, Wood CG, Atkins MB, Dutcher JP, Wilding G, DiPaola R. Effects of adjuvant sorafenib and sunitinib on cardiac function in renal cell carcinoma patients without overt metastases:results from ASSURE, ECOG2805. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 25967143 DOI: 10.1158/1078-0432.Ccr-15-0215 |
0.361 |
|
| 2015 |
Huang W, Eickhoff JC, Mehraein-Ghomi F, Church DR, Wilding G, Basu HS. Expression of spermidine/spermine N(1) -acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis. The Prostate. 75: 1150-9. PMID 25893668 DOI: 10.1002/Pros.22996 |
0.435 |
|
| 2015 |
Haas NB, Manola J, Uzzo RG, Atkins MB, Wilding G, Pins M, Jewett MAS, Kane CJ, Cella D, Wagner LI, Coomes B, Wood CG, Dutcher JP, Flaherty K, DiPaola RS. Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. Journal of Clinical Oncology. 33: 403-403. DOI: 10.1200/Jco.2015.33.7_Suppl.403 |
0.377 |
|
| 2015 |
Basu HS, Schrieber CL, Sperger JM, Naundorf M, Weichman AM, Mehraein-Ghomi F, Church DR, Lang JM, Wilding G. Abstract 2899: Mitophagy imparts enzalutamide resistance in prostate cancer Cancer Research. 75: 2899-2899. DOI: 10.1158/1538-7445.Am2015-2899 |
0.443 |
|
| 2014 |
DiPaola RS, Chen YH, Bubley GJ, Stein MN, Hahn NM, Carducci MA, Lattime EC, Gulley JL, Arlen PM, Butterfield LH, Wilding G. A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: ECOG 9802. European Urology. PMID 25533418 DOI: 10.1016/J.Eururo.2014.12.010 |
0.42 |
|
| 2014 |
Wisinski KB, Ledesma WM, Kolesar J, Wilding G, Liu G, Douglas J, Traynor AM, Albertini M, Mulkerin D, Bailey HH. A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. PMID 24986793 DOI: 10.1177/1078155214541572 |
0.411 |
|
| 2014 |
McNeel DG, Becker JT, Eickhoff JC, Johnson LE, Bradley E, Pohlkamp I, Staab MJ, Liu G, Wilding G, Olson BM. Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3692-704. PMID 24850844 DOI: 10.1158/1078-0432.Ccr-14-0169 |
0.391 |
|
| 2014 |
Mehraein-Ghomi F, Kegel SJ, Church DR, Schmidt JS, Reuter QR, Saphner EL, Basu HS, Wilding G. Targeting androgen receptor and JunD interaction for prevention of prostate cancer progression. The Prostate. 74: 792-803. PMID 24647988 DOI: 10.1002/Pros.22800 |
0.406 |
|
| 2014 |
Deming DA, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R, Espinoza-Delgado I, Wright J, Wilding G, Schelman WR. A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Investigational New Drugs. 32: 323-9. PMID 24114123 DOI: 10.1007/S10637-013-0035-8 |
0.41 |
|
| 2014 |
Schelman WR, Mohammed TA, Traynor AM, Kolesar JM, Marnocha RM, Eickhoff J, Keppen M, Alberti DB, Wilding G, Takebe N, Liu G. A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Investigational New Drugs. 32: 295-302. PMID 23860642 DOI: 10.1007/S10637-013-9999-7 |
0.436 |
|
| 2014 |
Wisinski KB, Cantu CA, Eickhoff JC, Osterby K, Tevaarwerk A, Liu G, Wilding G, Johnston S, Kolesar J. Cytochrome P450 interacting medication use in adult advanced solid tumor and phase I trial patients. Journal of Clinical Oncology. 32: 2591-2591. DOI: 10.1200/Jco.2014.32.15_Suppl.2591 |
0.34 |
|
| 2013 |
Madan RA, Stein WD, Wilkerson J, Dahut WL, Heery CR, Schlom J, Wilding G, DiPaola RS. Effect of PSA-tricom, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 57. PMID 28137072 DOI: 10.1200/Jco.2013.31.6_Suppl.57 |
0.447 |
|
| 2013 |
Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev V, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, De Bono JS, et al. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: LBA8. PMID 28136933 DOI: 10.1200/Jco.2013.31.6_Suppl.Lba8 |
0.438 |
|
| 2013 |
Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. The Lancet. Oncology. 14: 1307-16. PMID 24211163 DOI: 10.1016/S1470-2045(13)70479-0 |
0.499 |
|
| 2013 |
Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, ... Wilding G, et al. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Investigational New Drugs. 31: 1539-46. PMID 24114121 DOI: 10.1007/S10637-013-0029-6 |
0.438 |
|
| 2013 |
Lang JM, Wallace M, Becker JT, Eickhoff JC, Buehring B, Binkley N, Staab MJ, Wilding G, Liu G, Malkovsky M, McNeel DG. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. Clinical Genitourinary Cancer. 11: 407-15. PMID 23835291 DOI: 10.1016/J.Clgc.2013.04.029 |
0.43 |
|
| 2013 |
Rathkopf DE, Picus J, Hussain A, Ellard S, Chi KN, Nydam T, Allen-Freda E, Mishra KK, Porro MG, Scher HI, Wilding G. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 72: 537-44. PMID 23820963 DOI: 10.1007/S00280-013-2224-8 |
0.499 |
|
| 2013 |
Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. The Lancet. Oncology. 14: 882-92. PMID 23810788 DOI: 10.1016/S1470-2045(13)70240-7 |
0.395 |
|
| 2013 |
Rini BI, Garrett M, Poland B, Dutcher JP, Rixe O, Wilding G, Stadler WM, Pithavala YK, Kim S, Tarazi J, Motzer RJ. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. Journal of Clinical Pharmacology. 53: 491-504. PMID 23553560 DOI: 10.1002/Jcph.73 |
0.371 |
|
| 2013 |
Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, et al. Intermittent versus continuous androgen deprivation in prostate cancer. The New England Journal of Medicine. 368: 1314-25. PMID 23550669 DOI: 10.1056/Nejmoa1212299 |
0.445 |
|
| 2013 |
Gee J, Bailey H, Kim K, Kolesar J, Havighurst T, Tutsch KD, See W, Cohen MB, Street N, Levan L, Jarrard D, Wilding G. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. The Prostate. 73: 970-8. PMID 23335089 DOI: 10.1002/Pros.22644 |
0.441 |
|
| 2013 |
Lin J, Zahurak M, Beer TM, Ryan CJ, Wilding G, Mathew P, Morris M, Callahan JA, Gordon G, Reich SD, Carducci MA, Antonarakis ES. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. Urologic Oncology. 31: 581-8. PMID 21816640 DOI: 10.1016/J.Urolonc.2011.04.009 |
0.508 |
|
| 2013 |
Liu G, Chen YH, Kolesar J, Huang W, Dipaola R, Pins M, Carducci M, Stein M, Bubley GJ, Wilding G. Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urologic Oncology. 31: 211-8. PMID 21784672 DOI: 10.1016/J.Urolonc.2011.01.002 |
0.458 |
|
| 2013 |
Cetnar J, Wilding G, McNeel D, LoConte NK, McFarland TA, Eickhoff J, Liu G. A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Urologic Oncology. 31: 436-41. PMID 21481618 DOI: 10.1016/J.Urolonc.2011.02.007 |
0.484 |
|
| 2013 |
Wisinski KB, Tevaarwerk A, Bell M, Burkard ME, Eickhoff JC, Wilding G, LoConte NK, Traynor AM, Hoang T, Heideman J, Kolesar J, Liu G. A phase I study of MK-2206 in combination with lapatinib in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 31: 2607-2607. DOI: 10.1200/Jco.2013.31.15_Suppl.2607 |
0.384 |
|
| 2013 |
Michie CO, Sandhu SK, Schelman WR, Molife LR, Wilding G, Omlin AG, Kansra V, Brooks DG, Martell RE, Kaye SB, De Bono JS, Wenham RM. Final results of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carriers, sporadic ovarian, and castration resistant prostate cancer (CRPC). Journal of Clinical Oncology. 31: 2513-2513. DOI: 10.1200/Jco.2013.31.15_Suppl.2513 |
0.437 |
|
| 2013 |
Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S. Hereditary and sporadic cancers respond to niraparib Cancer Discovery. 3. DOI: 10.1158/2159-8290.Cd-Rw2013-148 |
0.325 |
|
| 2013 |
Mahalingam D, Cetnar J, Wilding G, Denmeade S, Sarantopoulos J, Kurman M, Carducci M. Abstract B244: A first-in-human phase 1 clinical study of G-202, a thapsigargin-based Prostate-Specific Membrane Antigen (PSMA) activated prodrug, in patients with advanced solid tumors. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B244 |
0.427 |
|
| 2012 |
Tangen CM, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Akdas A, Small EJ, Dawson NA, Donnelly BJ, Venner P, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, et al. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 4. PMID 28140795 DOI: 10.1200/Jco.2012.30.15_Suppl.4 |
0.419 |
|
| 2012 |
Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford ED, Vogelzang NJ, Powell IJ, Thompson IM. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). The Journal of Urology. 188: 1164-9. PMID 22921015 DOI: 10.1016/J.Juro.2012.06.046 |
0.457 |
|
| 2012 |
Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Science Translational Medicine. 4: 140ra86. PMID 22745436 DOI: 10.1126/Scitranslmed.3003886 |
0.439 |
|
| 2012 |
Amato RJ, Wilding G, Bubley G, Loewy J, Haluska F, Gross ME. Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. Clinical Genitourinary Cancer. 10: 232-8. PMID 22695254 DOI: 10.1016/J.Clgc.2012.05.001 |
0.499 |
|
| 2012 |
Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 1371-7. PMID 22430274 DOI: 10.1200/Jco.2011.36.4133 |
0.424 |
|
| 2012 |
Liu G, Chen YH, Dipaola R, Carducci M, Wilding G. Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group. Clinical Genitourinary Cancer. 10: 99-105. PMID 22386239 DOI: 10.1016/J.Clgc.2012.01.009 |
0.498 |
|
| 2012 |
McNeel DG, Smith HA, Eickhoff JC, Lang JM, Staab MJ, Wilding G, Liu G. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunology, Immunotherapy : Cii. 61: 1137-47. PMID 22210552 DOI: 10.1007/S00262-011-1193-1 |
0.528 |
|
| 2012 |
Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, Hutson TE, Kozloff M, Mathew P, Harmon CS, Wang SL, Chen I, Maneval EC, Logothetis CJ. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 23: 688-94. PMID 21821830 DOI: 10.1093/Annonc/Mdr349 |
0.496 |
|
| 2012 |
Holen K, DiPaola R, Liu G, Tan AR, Wilding G, Hsu K, Agrawal N, Chen C, Xue L, Rosenberg E, Stein M. A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors. Investigational New Drugs. 30: 1088-95. PMID 21424701 DOI: 10.1007/S10637-011-9653-1 |
0.43 |
|
| 2012 |
Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Medical Oncology (Northwood, London, England). 29: 761-7. PMID 21298497 DOI: 10.1007/S12032-011-9829-8 |
0.42 |
|
| 2012 |
Tevaarwerk A, Wilding G, Eickhoff J, Chappell R, Sidor C, Arnott J, Bailey H, Schelman W, Liu G. Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design. Investigational New Drugs. 30: 1039-45. PMID 21225315 DOI: 10.1007/S10637-010-9629-6 |
0.408 |
|
| 2012 |
Bruce JY, Eickhoff J, Pili R, Logan T, Carducci M, Arnott J, Treston A, Wilding G, Liu G. A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Investigational New Drugs. 30: 794-802. PMID 21174224 DOI: 10.1007/S10637-010-9618-9 |
0.367 |
|
| 2012 |
Deming DA, Schelman WR, Lubner SJ, Mulkerin D, LoConte NK, Fioravanti S, Greten T, Eickhoff JC, Kolesar J, Compton K, Doyle LA, Wilding G, Duffy AG, Liu G. A phase I study of selumetinib (AZD6244/ARRY-142866) in combination with cetuximab (cet) in refractory solid tumors and KRAS mutant colorectal cancer (CRC). Journal of Clinical Oncology. 30: 3103-3103. DOI: 10.1200/Jco.2012.30.15_Suppl.3103 |
0.382 |
|
| 2012 |
LoConte NK, Tevaarwerk A, Kolesar J, Holen KD, Lubner SJ, Mulkerin D, Schelman WR, Razak ARA, Siu LL, Eickhoff JC, Carmichael L, Wilding G, Ivy SP, Liu G. A phase I study of the gamma-secretase inhibitor RO4929097 and capecitabine in refractory solid tumors. Journal of Clinical Oncology. 30: 3101-3101. DOI: 10.1200/Jco.2012.30.15_Suppl.3101 |
0.412 |
|
| 2012 |
Schmidt J, Kegel S, Mehraein-Ghomi F, Saphner E, Reuter Q, Church D, Hoffmann FM, Basu HS, Wilding G. Abstract 2844: Inhibiting androgen receptor and JunD protein interaction to prevent prostate cancer progression Cancer Research. 72: 2844-2844. DOI: 10.1158/1538-7445.Am2012-2844 |
0.403 |
|
| 2012 |
Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, DeMarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy (Science Translational Medicine) Science Translational Medicine. 4. DOI: 10.1126/Scitranslmed.3004546 |
0.401 |
|
| 2011 |
Lang JM, Eickhoff JC, Binkley NC, Staab MJ, Liu G, Wilding G, McNeel DG. Randomized phase II trial evaluating different schedules of zoledronic acid administration on bone mineral density in patients with stage D prostate cancer beginning androgen deprivation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4643. PMID 28023932 DOI: 10.1200/Jco.2011.29.15_Suppl.4643 |
0.31 |
|
| 2011 |
Stein MN, Khan I, Hussain M, Liu G, Wilding G, Posadas EM, Stadler WM, Jeyamohan C, Eddy S, DiPaola RS. Phase II study of AT-101 to abrogate Bcl-2-mediated resistance to androgen-deprivation therapy (ADT) in patients (pts) with newly diagnosed androgen-dependent metastatic prostate cancer (ADMPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 137. PMID 27968504 DOI: 10.1200/jco.2011.29.7_suppl.137 |
0.396 |
|
| 2011 |
Lang JM, Staab MJ, Liu G, Wilding G, McNeel DG. Phase I dose-escalation trial of tremelimumab in combination with bicalutamide in patients with recurrent prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 174. PMID 27968439 DOI: 10.1200/Jco.2011.29.7_Suppl.174 |
0.402 |
|
| 2011 |
Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Martell B, Hariharan S, Figlin RA. Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: LBA308. PMID 27968383 DOI: 10.1200/jco.2011.29.7_suppl.lba308 |
0.301 |
|
| 2011 |
Lang JM, Kaikobad MR, Wallace M, Staab MJ, Horvath DL, Wilding G, Liu G, Eickhoff JC, McNeel DG, Malkovsky M. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunology, Immunotherapy : Cii. 60: 1447-60. PMID 21647691 DOI: 10.1007/S00262-011-1049-8 |
0.364 |
|
| 2011 |
Yu EY, Massard C, Gross ME, Carducci MA, Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC, Paliwal P, Fizazi K. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology. 77: 1166-71. PMID 21539969 DOI: 10.1016/J.Urology.2011.01.006 |
0.457 |
|
| 2011 |
Heath EI, Blumenschein GR, Cohen RB, Lorusso PM, Loconte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemotherapy and Pharmacology. 68: 703-12. PMID 21140147 DOI: 10.1007/S00280-010-1536-1 |
0.42 |
|
| 2011 |
Rathkopf D, Liu G, Carducci MA, Eisenberger MA, Anand A, Morris MJ, Slovin SF, Sasaki Y, Takahashi S, Ozono S, Fung NK, Cheng S, Gan J, Gottardis M, Obermeier MT, ... ... Wilding G, et al. Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 880-7. PMID 21131556 DOI: 10.1158/1078-0432.Ccr-10-2955 |
0.494 |
|
| 2011 |
Jonker DJ, Rosen LS, Sawyer MB, de Braud F, Wilding G, Sweeney CJ, Jayson GC, McArthur GA, Rustin G, Goss G, Kantor J, Velasquez L, Syed S, Mokliatchouk O, Feltquate DM, et al. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors Annals of Oncology. 22: 1413-1419. PMID 21131369 DOI: 10.1093/Annonc/Mdq599 |
0.422 |
|
| 2011 |
Basu HS, Mahlum A, Mehraein-Ghomi F, Kegel SJ, Guo S, Peters NR, Wilding G. Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA). Cancer Chemotherapy and Pharmacology. 67: 705-15. PMID 20512578 DOI: 10.1007/S00280-010-1364-3 |
0.324 |
|
| 2011 |
Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Investigational New Drugs. 29: 1465-74. PMID 20499131 DOI: 10.1007/S10637-010-9455-X |
0.5 |
|
| 2011 |
Holen KD, Belani CP, Wilding G, Ramalingam S, Volkman JL, Ramanathan RK, Vasist LS, Bowen CJ, Hodge JP, Dar MM, Ho PT. A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemotherapy and Pharmacology. 67: 447-54. PMID 20461380 DOI: 10.1007/S00280-010-1346-5 |
0.418 |
|
| 2011 |
Kolesar J, Brundage RC, Pomplun M, Alberti D, Holen K, Traynor A, Ivy P, Wilding G. Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients. Cancer Chemotherapy and Pharmacology. 67: 393-400. PMID 20440618 DOI: 10.1007/S00280-010-1331-Z |
0.303 |
|
| 2011 |
Traynor AM, Hewitt M, Liu G, Flaherty KT, Clark J, Freedman SJ, Scott BB, Leighton AM, Watson PA, Zhao B, O'Dwyer PJ, Wilding G. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 67: 305-14. PMID 20386909 DOI: 10.1007/S00280-010-1318-9 |
0.402 |
|
| 2011 |
Traynor AM, Thomas JP, Ramanathan RK, Mody TD, Alberti D, Wilding G, Bailey HH. Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies. Investigational New Drugs. 29: 316-22. PMID 19997959 DOI: 10.1007/S10637-009-9364-Z |
0.427 |
|
| 2011 |
Schelman WR, Liu G, Wilding G, Morris T, Phung D, Dreicer R. A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Investigational New Drugs. 29: 118-25. PMID 19763400 DOI: 10.1007/S10637-009-9318-5 |
0.518 |
|
| 2011 |
Kolesar JM, Lau E, Seo S, Eickhoff J, Kim K, Traynor A, Bailey H, Wilding G, Schelman W. Abstract 4396: Evaluation of gene expression and transcriptional activation in patients treated with vorinostat: Cancer Research. 71: 4396-4396. DOI: 10.1158/1538-7445.Am2011-4396 |
0.335 |
|
| 2011 |
Kegel S, Mehraein-Ghomi F, Reuter Q, Schmidt J, Church D, Hoffmann FM, Basu H, Wilding G. Abstract 2583: Targeting a novel pathway for prostate cancer therapy Cancer Research. 71: 2583-2583. DOI: 10.1158/1538-7445.Am2011-2583 |
0.405 |
|
| 2011 |
Mehraein-Ghomi F, Basu HS, Miyamoto S, Wilding G. Abstract 2165: Identification of a novel pathway of castrate resistant prostate cancer (CRPCa) growth Cancer Research. 71: 2165-2165. DOI: 10.1158/1538-7445.Am2011-2165 |
0.379 |
|
| 2011 |
Wenham R, Wilding G, Baird R, Sun L, Toniatti C, Stroh M, Carpenter C, de-Bono J, Sandhu S, Schelman W. First in human trial of the poly(ADP)-ribose polymerase inhibitor MK-4827 in patients with advanced cancer with antitumor activity in BRCA-deficient and sporadic ovarian cancers Gynecologic Oncology. 120. DOI: 10.1016/J.Ygyno.2010.12.015 |
0.384 |
|
| 2010 |
Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. Journal of the National Cancer Institute. 102: 1536-46. PMID 20858887 DOI: 10.1093/Jnci/Djq364 |
0.371 |
|
| 2010 |
Mehraein-Ghomi F, Basu HS, Church DR, Hoffmann FM, Wilding G. Androgen receptor requires JunD as a coactivator to switch on an oxidative stress generation pathway in prostate cancer cells. Cancer Research. 70: 4560-8. PMID 20460526 DOI: 10.1158/0008-5472.Can-09-3596 |
0.402 |
|
| 2010 |
DiPaola RS, Chen YH, Stein M, Vaughn D, Patrick-Miller L, Carducci M, Roth B, White E, Wilding G. A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899. Journal of Translational Medicine. 8: 20. PMID 20178647 DOI: 10.1186/1479-5876-8-20 |
0.437 |
|
| 2010 |
Choi BS, Alberti DB, Schelman WR, Kolesar JM, Thomas JP, Marnocha R, Eickhoff JC, Ivy SP, Wilding G, Holen KD. The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology. 66: 973-80. PMID 20127092 DOI: 10.1007/S00280-010-1250-Z |
0.368 |
|
| 2010 |
LoConte NK, Smith M, Alberti D, Bozeman J, Cleary JF, Setala AN, Wodtke G, Wilding G, Holen KD. Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy. Cancer Chemotherapy and Pharmacology. 65: 775-80. PMID 19649630 DOI: 10.1007/S00280-009-1084-8 |
0.393 |
|
| 2010 |
Traynor AM, Gordon MS, Alberti D, Mendelson DS, Munsey MS, Wilding G, Gammans RE, Read WL. A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors. Investigational New Drugs. 28: 509-15. PMID 19434370 DOI: 10.1007/S10637-009-9264-2 |
0.443 |
|
| 2010 |
Leal TA, Schelman WR, Traynor AM, Kolesar J, Marnocha RM, Eickhoff JC, Alberti DB, Takebe N, Wilding G. A phase I study of r-(-)-gossypol (AT-101, NSC 726190) in combination with cisplatin (P) and etoposide (E) in patients with advanced solid tumors and extensive-stage small cell lung cancer (ES-SCLC). Journal of Clinical Oncology. 28: e13030-e13030. DOI: 10.1200/Jco.2010.28.15_Suppl.E13030 |
0.319 |
|
| 2010 |
Chow SL, Lin Y, LoConte NK, Royds RB, Nekrassova TG, Ivy SP, Mauer J, Wilding G, Stoller R, Egorin MJ. Enrollment of and toxicity in patients 70 years and older on CTEP/NCI-sponsored, single-agent phase I studies from 1980 to 2005. Journal of Clinical Oncology. 28: 9119-9119. DOI: 10.1200/Jco.2010.28.15_Suppl.9119 |
0.369 |
|
| 2010 |
Garcia-Manero G, Chuah C, Wilding G, Chang J, Verstovsek S, Faderl S, Kantarjian HM, Ethirajulu K, Zhu J. Phase I Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies Blood. 116: 3292-3292. DOI: 10.1182/Blood.V116.21.3292.3292 |
0.417 |
|
| 2010 |
Huang W, Jarrard D, Ritter M, Waknitz M, Straus J, Wilding G. Abstract 4630: Seminal AMACR protein: a non-invasive test in the detection of prostate cancer Cancer Research. 70: 4630-4630. DOI: 10.1158/1538-7445.Am10-4630 |
0.437 |
|
| 2009 |
Yu E, Massard C, Gross M, Wilding G, Posadas E, Culine S, Carducci MA, Trudel G, Paliwal P, Sternberg C. A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CRPC) (CA180085). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5147. PMID 27964443 DOI: 10.1200/jco.2009.27.15_suppl.5147 |
0.408 |
|
| 2009 |
Vinson J, Mathew P, Beer TM, Carducci MA, Oh W, Small E, Wilding G, Higano C, Hussain M, Scher HI. Prostate cancer clinical trials consortium: A multicenter mechanism for the rapid design, development, and implementation of early phase clinical trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e16065. PMID 27963069 DOI: 10.1200/jco.2009.27.15_suppl.e16065 |
0.346 |
|
| 2009 |
Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Morris MJ, Hudes G, Calabrò F, Cheng S, Trudel GC, Paliwal P, Sternberg CN. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7421-8. PMID 19920114 DOI: 10.1158/1078-0432.Ccr-09-1691 |
0.497 |
|
| 2009 |
Burris HA, Taylor CW, Jones SF, Koch KM, Versola MJ, Arya N, Fleming RA, Smith DA, Pandite L, Spector N, Wilding G. A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6702-8. PMID 19825948 DOI: 10.1158/1078-0432.Ccr-09-0369 |
0.431 |
|
| 2009 |
Basu HS, Thompson TA, Church DR, Clower CC, Mehraein-Ghomi F, Amlong CA, Martin CT, Woster PM, Lindstrom MJ, Wilding G. A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Research. 69: 7689-95. PMID 19773450 DOI: 10.1158/0008-5472.Can-08-2472 |
0.404 |
|
| 2009 |
Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4462-8. PMID 19652060 DOI: 10.1200/Jco.2008.21.7034 |
0.438 |
|
| 2009 |
McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4047-54. PMID 19636017 DOI: 10.1200/Jco.2008.19.9968 |
0.418 |
|
| 2009 |
Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth BJ, Wilding G. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer. 115: 4090-5. PMID 19536901 DOI: 10.1002/Cncr.24467 |
0.447 |
|
| 2009 |
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3584-90. PMID 19487381 DOI: 10.1200/Jco.2008.20.1293 |
0.329 |
|
| 2009 |
Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, Dipaola RS, Crawford ED. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2450-6. PMID 19380444 DOI: 10.1200/Jco.2008.19.9810 |
0.437 |
|
| 2009 |
Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3172-6. PMID 19366825 DOI: 10.1158/1078-0432.Ccr-08-2985 |
0.453 |
|
| 2009 |
Traynor AM, Dubey S, Eickhoff JC, Kolesar JM, Schell K, Huie MS, Groteluschen DL, Marcotte SM, Hallahan CM, Weeks HR, Wilding G, Espinoza-Delgado I, Schiller JH. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: 522-6. PMID 19347984 DOI: 10.1097/Jto.0B013E3181952478 |
0.323 |
|
| 2009 |
Tevaarwerk AJ, Holen KD, Alberti DB, Sidor C, Arnott J, Quon C, Wilding G, Liu G. Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1460-5. PMID 19228747 DOI: 10.1158/1078-0432.Ccr-08-1599 |
0.367 |
|
| 2009 |
Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SE, Ryan C, Logothetis C, et al. Department of Defense prostate cancer clinical trials consortium: A new instrument for prostate cancer clinical research Clinical Genitourinary Cancer. 7: 51-57. PMID 19213669 DOI: 10.3816/Cgc.2009.N.009 |
0.433 |
|
| 2009 |
Motzer RJ, Hudes G, Wilding G, Schwartz LH, Hariharan S, Kempin S, Fayyad R, Figlin RA. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clinical Genitourinary Cancer. 7: 28-33. PMID 19213665 DOI: 10.3816/Cgc.2009.N.005 |
0.362 |
|
| 2009 |
Mulkerin D, Loconte NK, Holen KD, Thomas JP, Alberti D, Marnocha R, Kolesar J, Eickhoff J, Oliver K, Feierabend C, Wilding G. A phase I study of an oral simulated FOLFOX with high dose capecitabine Investigational New Drugs. 27: 461-468. PMID 19129971 DOI: 10.1007/S10637-008-9210-8 |
0.39 |
|
| 2009 |
Schelman WR, Morgan-Meadows S, Marnocha R, Lee F, Eickhoff J, Huang W, Pomplun M, Jiang Z, Alberti D, Kolesar JM, Ivy P, Wilding G, Traynor AM. A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 63: 1147-56. PMID 19082825 DOI: 10.1007/S00280-008-0890-8 |
0.424 |
|
| 2009 |
Attia S, Morgan-Meadows S, Holen KD, Bailey HH, Eickhoff JC, Schelman WR, Traynor AM, Mulkerin DL, Campbell TC, McFarland TA, Huie MS, Cleary JF, Tevaarwerk AJ, Alberti DB, Wilding G, et al. Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemotherapy and Pharmacology. 64: 45-51. PMID 18841362 DOI: 10.1007/S00280-008-0844-1 |
0.344 |
|
| 2009 |
Ignatoff JM, Chen YH, Greenberg RE, Pow-Sang JM, Messing EM, Wilding G. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group. Urologic Oncology. 27: 496-501. PMID 18639470 DOI: 10.1016/J.Urolonc.2008.05.004 |
0.32 |
|
| 2009 |
Dutcher J, Garrett M, Wilding G, Stadler WM, Pithavala Y, Kim S, Tarazi J, Rixe O, Rini BI. Abstract B213: Pharmacokinetics (PK) and efficacy of axitinib in patients (pts) with sorafenib‐refractory metastatic renal cell carcinoma (mRCC) Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B213 |
0.36 |
|
| 2009 |
Jeraj R, Vanderhoek M, Simoncic U, Perlman S, Alberti D, Wilding G, Liu G. WE-C-BRC-05: Use of FLT PET Imaging to Assess Tyrosine Kinase Inhibitor (TKI) Treatment Response Medical Physics. 36: 2761-2761. DOI: 10.1118/1.3182473 |
0.329 |
|
| 2008 |
Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Hudes GR, Cheng S, Paliwal P, Sternberg CN. Dasatinib in patients with hormone-refractory progressive prostate cancer: A phase II study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5156. PMID 27948244 DOI: 10.1200/jco.2008.26.15_suppl.5156 |
0.368 |
|
| 2008 |
Lardy H, Marwah A, Zhong W, Moore R, Marwah P, Thompson T, Wilding G. A test of rats' tolerance for 3β-acetoxyandrosta-1,5-dien-17-one ethylene ketal (ADEK), a new anti-androgen Journal of Steroid Biochemistry and Molecular Biology. 111: 60-65. PMID 18539452 DOI: 10.1016/J.Jsbmb.2007.11.008 |
0.378 |
|
| 2008 |
Dreicer R, Li H, Cooney MM, Wilding G, Roth BJ. Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group. Cancer. 112: 2671-5. PMID 18459175 DOI: 10.1002/Cncr.23503 |
0.436 |
|
| 2008 |
Liu G, Kolesar J, McNeel DG, Leith C, Schell K, Eickhoff J, Lee F, Traynor A, Marnocha R, Alberti D, Zwiebel J, Wilding G. A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2732-9. PMID 18451239 DOI: 10.1158/1078-0432.Ccr-07-1490 |
0.409 |
|
| 2008 |
Attia S, Eickhoff J, Wilding G, McNeel D, Blank J, Ahuja H, Jumonville A, Eastman M, Shevrin D, Glode M, Alberti D, Staab MJ, Horvath D, Straus J, Marnocha R, et al. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2437-43. PMID 18413835 DOI: 10.1158/1078-0432.Ccr-07-4274 |
0.468 |
|
| 2008 |
Mehraein-Ghomi F, Lee E, Church DR, Thompson TA, Basu HS, Wilding G. JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells. The Prostate. 68: 924-34. PMID 18386285 DOI: 10.1002/Pros.20737 |
0.625 |
|
| 2008 |
LoConte NK, Thomas JP, Alberti D, Heideman J, Binger K, Marnocha R, Utecht K, Geiger P, Eickhoff J, Wilding G, Kolesar J. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 63: 109-15. PMID 18322686 DOI: 10.1007/S00280-008-0719-5 |
0.469 |
|
| 2008 |
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, ... ... Wilding G, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1148-59. PMID 18309951 DOI: 10.1200/Jco.2007.12.4487 |
0.462 |
|
| 2008 |
Schelman W, Morgan-Meadows S, Bailey H, Holen K, Thomas JP, Eickhoff J, Brandon H, Oliver K, Alberti D, Wilding G. A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 62: 727-33. PMID 18172649 DOI: 10.1007/S00280-007-0656-8 |
0.446 |
|
| 2008 |
Hutson PR, Oettel K, Douglas J, Ritter M, Messing E, Staab MJ, Alberti D, Horvath D, Wilding G. Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test. Cancer Chemotherapy and Pharmacology. 62: 373-7. PMID 17922273 DOI: 10.1007/S00280-007-0613-6 |
0.325 |
|
| 2008 |
Chen Y, Wilding G, Gee J, DiPaola RP, Pins M, Carducci MA, Stein MN, Bubley G, Liu G. A phase II trial of lapatinib (GW572016) in patients with recurrent prostate cancer as evident by a rising PSA Journal of Clinical Oncology. 26: 5170-5170. DOI: 10.1200/JCO.2008.26.15_SUPPL.5170 |
0.379 |
|
| 2008 |
George DJ, Liu G, Wilding G, Hutson TE, Chen I, Chow Maneval E, Logothetis CJ, Zurita AJ. Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer (mHRPC) - preliminary results Journal of Clinical Oncology. 26: 5131-5131. DOI: 10.1200/JCO.2008.26.15_SUPPL.5131 |
0.369 |
|
| 2007 |
Lalich M, McNeel DG, Wilding G, Liu G. Endothelin receptor antagonists in cancer therapy. Cancer Investigation. 25: 785-94. PMID 18058475 DOI: 10.1080/07357900701522588 |
0.42 |
|
| 2007 |
Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. The Lancet. Oncology. 8: 975-84. PMID 17959415 DOI: 10.1016/S1470-2045(07)70285-1 |
0.431 |
|
| 2007 |
Aziz MH, Manoharan HT, Church DR, Dreckschmidt NE, Zhong W, Oberley TD, Wilding G, Verma AK. Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer. Cancer Research. 67: 8828-38. PMID 17875724 DOI: 10.1158/0008-5472.Can-07-1604 |
0.439 |
|
| 2007 |
Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Wilding G. Sunitinib efficacy against advanced renal cell carcinoma. The Journal of Urology. 178: 1883-7. PMID 17868732 DOI: 10.1016/J.Juro.2007.07.030 |
0.376 |
|
| 2007 |
Small EJ, Fontana J, Tannir N, DiPaola RS, Wilding G, Rubin M, Iacona RB, Kabbinavar FF. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. Bju International. 100: 765-9. PMID 17822457 DOI: 10.1111/J.1464-410X.2007.07121.X |
0.479 |
|
| 2007 |
Dreicer R, Li S, Manola J, Haas NB, Roth BJ, Wilding G. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer. 110: 759-63. PMID 17594721 DOI: 10.1002/Cncr.22839 |
0.407 |
|
| 2007 |
Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 110: 556-63. PMID 17577218 DOI: 10.1002/Cncr.22811 |
0.484 |
|
| 2007 |
Bailey HH, Alberti DB, Thomas JP, Mulkerin DL, Binger KA, Gottardis MM, Martell RE, Wilding G. Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3623-9. PMID 17510207 DOI: 10.1158/1078-0432.Ccr-07-0158 |
0.432 |
|
| 2007 |
Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, et al. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. The Journal of Urology. 177: 1777-81. PMID 17437819 DOI: 10.1016/J.Juro.2007.01.028 |
0.387 |
|
| 2007 |
Attia S, Eickhoff J, Wilding G, Blank J, Rezazadeh H, Shevrin D, Glode M, Jumonville A, Eastman M, Liu G. Randomized phase II trial of docetaxel, with or without doxercalciferol, in advanced, androgen-independent prostate cancer Journal of Clinical Oncology. 25: 5119-5119. DOI: 10.1200/Jco.2007.25.18_Suppl.5119 |
0.446 |
|
| 2007 |
Schelman WR, Kolesar J, Schell K, Marnocha R, Eickhoff J, Alberti D, Wilding G, Bailey H. A phase I study of vorinostat in combination with bortezomib in refractory solid tumors Journal of Clinical Oncology. 25: 3573-3573. DOI: 10.1200/Jco.2007.25.18_Suppl.3573 |
0.414 |
|
| 2007 |
Stein MN, Tan A, Taber K, Fernandez R, Agrawal NG, Vandendries E, Hsu K, Walker A, Holen K, Wilding G. Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in patients with solid tumors Journal of Clinical Oncology. 25: 2548-2548. DOI: 10.1200/Jco.2007.25.18_Suppl.2548 |
0.338 |
|
| 2006 |
Lalich M, Wilding G, Kolesar J, McNeel DG, Schell K, Leith C, Chappell R, Marnocha R, Alberti D, Liu G. A phase I study of antisense Bcl-2 oligonucleotide (G3139) in combination with carboplatin (C) and paclitaxel (T) in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 13006. PMID 27955410 DOI: 10.1200/Jco.2006.24.18_Suppl.13006 |
0.334 |
|
| 2006 |
Chang JE, Morgan Meadows S, Traynor A, Kolesar J, Marnocha R, Lee F, Eickoff J, Beth E, Binger K, Wilding G. A phase I study of triapine in combination with doxorubicin in refractory tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 13168. PMID 27954315 DOI: 10.1200/Jco.2006.24.18_Suppl.13168 |
0.389 |
|
| 2006 |
Stein MN, Rubin EH, Scott PD, Fernandez R, Agrawal NG, Hsu K, Walker A, Holen K, Wilding G. Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 2001. PMID 27952777 DOI: 10.1200/Jco.2006.24.18_Suppl.2001 |
0.352 |
|
| 2006 |
Attia S, Wilding G. Novel antioxidant technology for prostate cancer chemoprevention and treatment. Expert Opinion On Therapeutic Patents. 16: 1255-67. PMID 20144058 DOI: 10.1517/13543776.16.9.1255 |
0.422 |
|
| 2006 |
Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3984-90. PMID 16921051 DOI: 10.1200/Jco.2006.06.4246 |
0.436 |
|
| 2006 |
Messing E, Kim KM, Sharkey F, Schultz M, Parnes H, Kim D, Saltzstein D, Wilding G. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. The Journal of Urology. 176: 500-4. PMID 16813878 DOI: 10.1016/J.Juro.2006.03.061 |
0.383 |
|
| 2006 |
Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. Sunitinib in patients with metastatic renal cell carcinoma. Jama. 295: 2516-24. PMID 16757724 DOI: 10.1001/Jama.295.21.2516 |
0.428 |
|
| 2006 |
Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. The Lancet. Oncology. 7: 472-9. PMID 16750497 DOI: 10.1016/S1470-2045(06)70700-8 |
0.421 |
|
| 2006 |
Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, Ummersen Lv, Yu DC, Aimi J, Ando D, Kirn D, Wilding G. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Molecular Therapy. 14: 107-117. PMID 16690359 DOI: 10.1016/J.Ymthe.2006.02.011 |
0.489 |
|
| 2006 |
Gray R, Manola J, Saxman S, Wright J, Dutcher J, Atkins M, Carducci M, See W, Sweeney C, Liu G, Stein M, Dreicer R, Wilding G, DiPaola RS. Phase II clinical trial design: Methods in translational research from the genitourinary committee at the Eastern Cooperative Oncology Group Clinical Cancer Research. 12: 1966-1969. PMID 16609005 DOI: 10.1158/1078-0432.Ccr-05-1136 |
0.343 |
|
| 2006 |
Wilding G, Soulie P, Trump D, Das-Gupta A, Small E. Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Cancer. 106: 1917-24. PMID 16568471 DOI: 10.1002/cncr.21831 |
0.403 |
|
| 2006 |
Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 16-24. PMID 16330672 DOI: 10.1200/Jco.2005.02.2574 |
0.369 |
|
| 2006 |
Huie M, Oettel K, Ummersen LV, Kyung MK, Zhang Y, Staab MJ, Horvath D, Marnocha R, Douglas J, Drezen A, Alberti D, Wilding G. Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma Investigational New Drugs. 24: 255-260. PMID 16205854 DOI: 10.1007/S10637-005-3903-Z |
0.394 |
|
| 2006 |
Malkovsky M, McNeel DG, Wallace M, Schell K, Wilding G, Eikhoff J, Staab MJ, Horvath D, Straus J, Liu G. Use of zoledronic acid (ZA) and interleukin-2 (IL-2) to activate and expand Vγ9Vδ2 T cells for therapeutic use in patients with metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology. 24: 14607-14607. DOI: 10.1200/Jco.2006.24.18_Suppl.14607 |
0.337 |
|
| 2006 |
McNeel DG, Dunphy EJ, Johnson LE, Frye TP, Staab MJ, Horvath DL, Straus J, Alberti D, Liu G, Wilding G. A plasmid DNA vaccine encoding prostatic acid phosphatase (PAP) elicits antigen-specific T cells in patients with stage D0 prostate cancer Journal of Clinical Oncology. 24: 14570-14570. DOI: 10.1200/Jco.2006.24.18_Suppl.14570 |
0.432 |
|
| 2006 |
Meadows SM, Ummersen LV, Brandon H, Oliver K, Houston M, Eickhoff J, Wilding G. A dose escalation trial of fixed dose gemcitabine and capecitabine Journal of Clinical Oncology. 24: 12026-12026. DOI: 10.1200/Jco.2006.24.18_Suppl.12026 |
0.418 |
|
| 2006 |
Schelman WR, Holen K, Mulkerin D, Kolesar J, Thomas J, Kruse M, Oliver K, Marnocha R, Eickhoff J, Wilding G. A phase I study of triapine in combination with irinotecan in refractory tumors Journal of Clinical Oncology. 24: 12011-12011. DOI: 10.1200/Jco.2006.24.18_Suppl.12011 |
0.419 |
|
| 2006 |
Gross M, Amato R, Mushtaq M, Wilding G, Bubley G. 362 POSTER A phase 2 trial of AP23573, an mTOR inhibitor, in patients (pts) with taxane-resistant androgen-independent prostate cancer (AIPC) European Journal of Cancer Supplements. 4: 112. DOI: 10.1016/S1359-6349(06)70367-6 |
0.366 |
|
| 2005 |
Hegeman RB, Mulkerin D, Thomas J, Alberti D, Binger K, Marnocha R, Kolesar J, Wilding G. Phase I study of oxaliplatin in combination with 5-fluorouracil (5-FU), leucovorin (LV) and capecitabine (ORAL FOLFOX-6) in patients with advanced or metastatic solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2058. PMID 27946895 DOI: 10.1200/Jco.2005.23.16_Suppl.2058 |
0.451 |
|
| 2005 |
Dubey S, Hutson P, Alberti D, Arzoomanian R, Binger K, Volkman J, Feierabend C, Wilding G, Schiller JH. Phase I study of docetaxel and topotecan in patients with advanced malignancies. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 11: 131-8. PMID 16595064 DOI: 10.1191/1078155205Jp161Oa |
0.428 |
|
| 2005 |
Zlotocha S, Staab MJ, Horvath D, Straus J, Dobratz J, Oliver K, Wasielewski S, Alberti D, Liu G, Wilding G, Eickhoff J, McNeel DG. A phase I study of a DNA vaccine targeting prostatic Acid phosphatase in patients with stage D0 prostate cancer. Clinical Genitourinary Cancer. 4: 215-8. PMID 16425992 DOI: 10.3816/Cgc.2005.N.036 |
0.417 |
|
| 2005 |
Huie M, Carducci MA, Liu G, Wilding G, Marnocha R, Izquierda M, Thomas J. Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors. American Journal of Clinical Oncology. 28: 613-617. PMID 16317274 DOI: 10.1097/01.Coc.0000171281.13541.90 |
0.405 |
|
| 2005 |
McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, Wilding G. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 7851-60. PMID 16278408 DOI: 10.1158/1078-0432.Ccr-05-0262 |
0.425 |
|
| 2005 |
Dutcher JP, Leon L, Manola J, Friedland DM, Roth B, Wilding G. Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study Cancer. 104: 2392-2399. PMID 16222691 DOI: 10.1002/cncr.21473 |
0.3 |
|
| 2005 |
Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, Fife K, Armstrong V, Treston A, Sidor C, Wilding G. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 6625-33. PMID 16166441 DOI: 10.1158/1078-0432.Ccr-05-0440 |
0.469 |
|
| 2005 |
Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5464-73. PMID 16027440 DOI: 10.1200/Jco.2005.04.143 |
0.329 |
|
| 2005 |
Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5474-83. PMID 16027439 DOI: 10.1200/Jco.2005.04.192 |
0.381 |
|
| 2005 |
Dy GK, Thomas JP, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger K, Pitot HC, Alberts SR, Hanson LJ, Marnocha R, Tutsch K, Kaufmann SH, Adjei AA. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 3410-6. PMID 15867242 DOI: 10.1158/1078-0432.Ccr-04-2068 |
0.433 |
|
| 2005 |
Church DR, Lee E, Thompson TA, Basu HS, Ripple MO, Ariazi EA, Wilding G. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells. The Prostate. 63: 155-68. PMID 15486991 DOI: 10.1002/Pros.20172 |
0.611 |
|
| 2005 |
Holen KD, Belani CP, Wilding G, Ramalingam S, Heideman JL, Ramanathan RK, Bowen CJ, Williams DD, Hodge JP, Dar MM. Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor Journal of Clinical Oncology. 23: 2000-2000. DOI: 10.1200/Jco.2006.24.18_Suppl.2000 |
0.396 |
|
| 2005 |
Motzer RJ, Rini BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, Bukowski RM, George DJ, Kim ST, Baum CM. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) Journal of Clinical Oncology. 23: 4508-4508. DOI: 10.1200/Jco.2005.23.16_Suppl.4508 |
0.368 |
|
| 2005 |
Kibei AS, Kattan MW, Picus J, Dreicer R, Klein EA, Wilding G, Jarrard DF, Roth B, Cookson MS, Petrylak DP, Ghatta G, Nelson JB, Beer TM, Dipaola R, Partin AW, et al. 1589: Adjuvant Weekly Docetaxel for High-Risk Prostate Cancer Patients After Radical Prostatectomy The Journal of Urology. 173: 222-222. DOI: 10.1016/S0022-5347(18)33781-9 |
0.424 |
|
| 2004 |
Holen KD, Syed S, Hannah AL, Binger K, Wood L, Zhou Y, Cropp GF, Johnson RG, Rowinsky E, Wilding G. Phase I study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2024. PMID 28015590 DOI: 10.1200/Jco.2004.22.14_Suppl.2024 |
0.37 |
|
| 2004 |
Hegeman RB, Liu G, Wilding G, McNeel DG. Newer therapies in advanced prostate cancer. Clinical Prostate Cancer. 3: 150-6. PMID 15636681 DOI: 10.3816/Cgc.2004.N.025 |
0.453 |
|
| 2004 |
Wilding G, Remington P. Period analysis of prostate cancer survival. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 407-9. PMID 15572729 DOI: 10.1200/Jco.2005.09.906 |
0.403 |
|
| 2004 |
Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, Kolesar J, Arzoomanian R, Alberti D, Wilding G. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 7450-6. PMID 15569974 DOI: 10.1158/1078-0432.Ccr-03-0406 |
0.42 |
|
| 2004 |
Schulz CA, Mehta MP, Badie B, McGinn CJ, Robins HI, Hayes L, Chappell R, Volkman J, Binger K, Arzoomanian R, Simon K, Alberti D, Feierabend C, Tutsch KD, Kunugi KA, ... Wilding G, et al. Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study. International Journal of Radiation Oncology, Biology, Physics. 59: 1107-15. PMID 15234045 DOI: 10.1016/J.Ijrobp.2003.12.007 |
0.391 |
|
| 2004 |
Bailey HH, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Marnocha R, Holstein SA, Stewart J, Lewis KA, Hohl RJ. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days. Cancer Chemotherapy and Pharmacology. 54: 368-76. PMID 15205914 DOI: 10.1007/S00280-004-0788-Z |
0.379 |
|
| 2004 |
Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, Whiteside TL, Schlom J, Wilding G, Weiner LM. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2122-32. PMID 15169798 DOI: 10.1200/Jco.2004.08.083 |
0.451 |
|
| 2004 |
Forouzannia A, Schiller J, Berlin J, Hutson P, Boothman D, Storer B, Wilding G, Mehta M. A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies Lung Cancer. 44: 111-119. PMID 15013589 DOI: 10.1016/J.Lungcan.2003.10.005 |
0.408 |
|
| 2004 |
Liu G, Gandara DR, Lara PN, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim KM, Wilding G. A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer Clinical Cancer Research. 10: 924-928. PMID 14871968 DOI: 10.1158/1078-0432.Ccr-03-0050 |
0.547 |
|
| 2004 |
Hande KR, Collier M, Paradiso L, Stuart-Smith J, Dixon M, Clendeninn N, Yeun G, Alberti D, Binger K, Wilding G. Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 909-15. PMID 14871966 DOI: 10.1158/1078-0432.Ccr-0981-3 |
0.395 |
|
| 2004 |
Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, ... ... Wilding G, et al. Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group Journal of Clinical Oncology. 22: 537-556. PMID 14752077 DOI: 10.1200/Jco.2004.07.099 |
0.428 |
|
| 2004 |
Wilding G, King D, Tutsch K, Pomplun M, Feierabend C, Alberti D, Arzoomanian R. Phase I trial of the polyamine analog N1, N 14-diethylhomospermine (DEHSPM) in patients with advanced solid tumors Investigational New Drugs. 22: 131-138. PMID 14739661 DOI: 10.1023/B:Drug.0000011789.79368.Ae |
0.412 |
|
| 2004 |
Dipaola RS, Manola J, Li S, Vaughn D, Roth B, Wilding G. A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic hormone refractory prostate cancer: results of ECOG 3899 Journal of Clinical Oncology. 22: 4594-4594. DOI: 10.1200/JCO.2004.22.90140.4594 |
0.366 |
|
| 2004 |
Pandite L, Burris HA, Jones S, Wilding G, Taylor C, Versola MJ, Smith DA, Stead A, Koch KM, Spector NL. A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors Journal of Clinical Oncology. 22: 3179-3179. DOI: 10.1200/Jco.2004.22.90140.3179 |
0.38 |
|
| 2004 |
Versola M, Burris HA, Jones S, Wilding G, Taylor C, Pandite L, Smith DA, Stead A, Spector NL. Clinical activity of GW572016 in EGF10003 in patients with solid tumors Journal of Clinical Oncology. 22: 3047-3047. DOI: 10.1200/Jco.2004.22.90140.3047 |
0.384 |
|
| 2004 |
Chu QS, Holen KD, Rowinsky EK, Wilding G, Volkman JL, Orr JB, Williams DD, Hodge JP, Sabry J. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days Journal of Clinical Oncology. 22: 2078-2078. DOI: 10.1200/Jco.2004.22.90140.2078 |
0.305 |
|
| 2004 |
Messing EM, Manola J, Yao J, Kiernan M, Crawford ED, Wilding G, di'SantAgnese PA. 1455: Immediate VS Delayed Hormonal Therapy (HT) in Patients with Nodal Positive (N+) Prostate Cancer Who Had Undergone Radical Prostatectomy (RP) + Pelvic Lymphadenectomy (LND): Results of Central Pathology Review (CPR) Journal of Urology. 171: 383-383. DOI: 10.1016/S0022-5347(18)38680-4 |
0.382 |
|
| 2004 |
Jarrard DF, Schwarze SR, Fu V, Wilding G, Church D, Brummel S. 1453: The Induction of Cellular Senescence During Therapy for Advanced Prostate Cancer Journal of Urology. 171: 382-383. DOI: 10.1016/S0022-5347(18)38678-6 |
0.429 |
|
| 2003 |
Liu G, Oettel K, Bailey H, Ummersen LV, Tutsch K, Staab MJ, Horvath D, Alberti D, Arzoomanian R, Rezazadeh H, McGovern J, Robinson E, DeMets D, Wilding G. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Investigational New Drugs. 21: 367-72. PMID 14578686 DOI: 10.1023/A:1025437115182 |
0.477 |
|
| 2003 |
Frydman B, Blokhin AV, Brummel S, Wilding G, Maxuitenko Y, Sarkar A, Bhattacharya S, Church D, Reddy VK, Kink JA, Marton LJ, Valasinas aA, Basu HS. Cyclopropane-containing polyamine analogues are efficient growth inhibitors of a human prostate tumor xenograft in nude mice. Journal of Medicinal Chemistry. 46: 4586-4600. PMID 14521420 DOI: 10.1021/Jm030175U |
0.409 |
|
| 2003 |
Liu G, Wilding G, Staab MJ, Horvath D, Miller K, Dresen A, Alberti D, Arzoomanian R, Chappell R, Bailey HH. Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 4077-83. PMID 14519629 |
0.319 |
|
| 2003 |
Morgan-Meadows S, Dubey S, Gould M, Tutsch K, Marnocha R, Arzoomanin R, Alberti D, Binger K, Feierabend C, Volkman J, Ellingen S, Black S, Pomplun M, Wilding G, Bailey H. Phase I trial of perillyl alcohol administered four times daily continuously. Cancer Chemotherapy and Pharmacology. 52: 361-6. PMID 12904896 DOI: 10.1007/S00280-003-0684-Y |
0.34 |
|
| 2003 |
Stadler W, Wilding G. Angiogenesis inhibitors in genitourinary cancers Critical Reviews in Oncology Hematology. 46: 41-47. PMID 12850526 DOI: 10.1016/S1040-8428(03)00063-5 |
0.38 |
|
| 2003 |
Liu G, Bailey HH, Arzoomanian RZ, Alberti D, Binger K, Volkman J, Feierabend C, Marnocha R, Wilding G, Thomas JP. Gemcitabine, Paclitaxel, and piritrexim: a phase I study. American Journal of Clinical Oncology. 26: 280-4. PMID 12796601 DOI: 10.1097/01.Coc.0000081607.16287.6F |
0.428 |
|
| 2003 |
Bauer JA, Thompson TA, Church DR, Ariazi EA, Wilding G. Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1alpha,24-dihydroxyvitamin D2. The Prostate. 55: 159-67. PMID 12692781 DOI: 10.1002/Pros.10219 |
0.359 |
|
| 2003 |
Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Dresen A, Geiger P, Pluda J, Fogler W, Schiller JH, Wilding G. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 223-31. PMID 12525513 DOI: 10.1200/Jco.2003.12.120 |
0.416 |
|
| 2003 |
Koch K, Lee D, Jones S, Stead A, Versola M, Burris H, Wilding G, Taylor C, Spector N, Smith D. 559 Pharmacokinetics of GW572016 in an ascending dose tolerability study of phase I cancer patients European Journal of Cancer Supplements. 1: S169. DOI: 10.1016/S1359-6349(03)90591-X |
0.341 |
|
| 2002 |
Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, Simon K, Feierabend C, Binger K, Marnocha R, Dresen A, Wilding G. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemotherapy and Pharmacology. 50: 465-72. PMID 12451473 DOI: 10.1007/S00280-002-0527-2 |
0.403 |
|
| 2002 |
Roth BJ, Manola J, Dreicer R, Graham D, Wilding G. Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): A phase II trial of the Eastern Cooperative Oncology Group Investigational New Drugs. 20: 425-429. PMID 12448661 DOI: 10.1023/A:1020675017737 |
0.339 |
|
| 2002 |
Morgan-Meadows S, Thomas JP, Mulkerin D, Berlin JD, Bailey H, Binger K, Volkman J, Alberti D, Feierabend C, Marrocha R, Arzoomanian RZ, Wilding G. Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy. Investigational New Drugs. 20: 377-82. PMID 12448654 DOI: 10.1023/A:1020673928704 |
0.422 |
|
| 2002 |
Lee YF, Lin WJ, Huang J, Messing EM, Chan FL, Wilding G, Chang C. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Research. 62: 6039-44. PMID 12414626 |
0.325 |
|
| 2002 |
Liu G, Oettel K, Ripple G, Staab MJ, Horvath D, Alberti D, Arzoomanian R, Marnocha R, Bruskewitz R, Mazess R, Bishop C, Bhattacharya A, Bailey H, Wilding G. Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 2820-7. PMID 12231522 |
0.31 |
|
| 2002 |
Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Randomized Study of Three Different Doses of Suramin Administered With a Fixed Dosing Schedule in Patients With Advanced Prostate Cancer: Results of Intergroup 0159, Cancer and Leukemia Group B 9480 Journal of Clinical Oncology. 20: 3369-3375. PMID 12177096 DOI: 10.1200/Jco.2002.10.022 |
0.487 |
|
| 2002 |
Hinton S, Catalano P, Einhorn LH, Loehrer PJ, Kuzel T, Vaughn D, Wilding G. Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors (E9897): A Trial of the Eastern Cooperative Oncology Group Journal of Clinical Oncology. 20: 1859-1863. PMID 11919245 DOI: 10.1200/Jco.2002.07.158 |
0.431 |
|
| 2001 |
Thomas JP, Arzoomanian R, Alberti D, Feierabend C, Binger K, Tutsch KD, Steele T, Marnocha R, Smith C, Smith S, MacDonald J, Wilding G, Bailey H. Phase I clinical and pharmacokinetic trial of irofulven. Cancer Chemotherapy and Pharmacology. 48: 467-72. PMID 11800027 DOI: 10.1007/S002800100365 |
0.417 |
|
| 2001 |
Wu S, Hafez G, Zhang J, Newton M, Chen A, Lange J, Wilding G. Identification of the prostate cancer micro-foci with chromosome 8p deletion at the tumor interface area by histopathological-FISH parallel examination. International Journal of Oncology. 19: 1143-1147. PMID 11713582 DOI: 10.3892/Ijo.19.6.1143 |
0.403 |
|
| 2001 |
Walczak J, Wood H, Wilding G, Williams T, Bishop CW, Carducci M. Prostate cancer prevention strategies using antiproliferative or differentiating agents. Urology. 57: 81-5. PMID 11295601 DOI: 10.1016/S0090-4295(00)00947-X |
0.427 |
|
| 2001 |
Nelson WG, Wilding G. Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents. Urology. 57: 56-63. PMID 11295596 DOI: 10.1016/S0090-4295(00)00942-0 |
0.439 |
|
| 2001 |
Lieberman R, Nelson WG, Sakr WA, Meyskens FL, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations. Urology. 57: 4-27. PMID 11295590 DOI: 10.1016/S0090-4295(00)00931-6 |
0.456 |
|
| 2001 |
Small E, Carducci M, Wilding G. A phase dose finding trial of the intravenous injection of CV787, a prostate specific antigen-dependent cytolytic adenovirus in patients with advanced hormone refractory prostate cancer (HRPC) European Journal of Cancer. 37: S217-S218. DOI: 10.1016/S0959-8049(01)81289-2 |
0.403 |
|
| 2000 |
Ochoa L, Hurwitz HI, Wilding G, Cohen D, Thomas JP, Schwartz G, Monroe P, Petros WP, Ertel VP, Hsieh A, Hoffman C, Drengler R, Magnum S, Rowinsky EK. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies Annals of Oncology. 11: 1313-1322. PMID 11106122 DOI: 10.1023/A:1008379802642 |
0.387 |
|
| 2000 |
Ryan CJ, Wilding G. Angionesis inhibitors: New agents in cancer therapy Drugs and Aging. 17: 249-255. PMID 11087003 DOI: 10.2165/00002512-200017040-00001 |
0.323 |
|
| 2000 |
Kasimis B, Wilding G, Kreis W, Feuerman M, Chang V, Hwang S, Steafather H, Cogswell J, Rae C, Blumenfrucht M. Survival of patients who had salvage castration after failure on bicalutamide monotherapy for stage (D2) prostate cancer. Cancer Investigation. 18: 602-608. PMID 11036467 DOI: 10.3109/07357900009032826 |
0.466 |
|
| 2000 |
Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M. Phase III Trial of Interferon Alfa-2a With or Without 13-cis-Retinoic Acid for Patients With Advanced Renal Cell Carcinoma Journal of Clinical Oncology. 18: 2972-2980. PMID 10944130 DOI: 10.1200/Jco.2000.18.16.2972 |
0.424 |
|
| 2000 |
Dreicer R, Manola J, Roth BJ, Cohen MB, Hatfield AK, Wilding G. Phase II Study of Cisplatin and Paclitaxel in Advanced Carcinoma of the Urothelium: An Eastern Cooperative Oncology Group Study Journal of Clinical Oncology. 18: 1058-1061. PMID 10694557 DOI: 10.1200/Jco.2000.18.5.1058 |
0.445 |
|
| 2000 |
Fields-Jones S, Koletsky A, Wilding G, O'Rourke M, O'Rourke T, Eckardt J, Yates B, McGuirt C, Burris HA. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 10: 1307-10. PMID 10631457 DOI: 10.1023/A:1008315106697 |
0.382 |
|
| 2000 |
Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, ... ... Wilding G, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 3461-7. PMID 10550143 DOI: 10.1200/Jco.1999.17.11.3461 |
0.462 |
|
| 1999 |
Witte RS, Lipsitz S, Goodman TL, Asbury RF, Wilding G, Strnad CM, Smith TJ, Haller DG. A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer. Investigational New Drugs. 17: 173-7. PMID 10638488 DOI: 10.1023/A:1006327418043 |
0.383 |
|
| 1999 |
Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. The New England Journal of Medicine. 341: 1781-8. PMID 10588962 DOI: 10.1056/Nejm199912093412401 |
0.412 |
|
| 1999 |
Robins HI, Tutsch K, Katschinski DM, Jacobson E, Mehta M, Olsen M, Cohen JD, Tiggelaar CL, Arzoomanian RZ, Alberti D, Feierabend C, Wilding G. Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer. Journal of Clinical Oncology. 17: 2922-2931. PMID 10561372 DOI: 10.1200/Jco.1999.17.9.2922 |
0.392 |
|
| 1999 |
Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Feierabend C, Robins HI, Spriggs DR, Wilding G. Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812). Investigational New Drugs. 17: 63-72. PMID 10555124 DOI: 10.1023/A:1006223100561 |
0.411 |
|
| 1999 |
Messing EM, Love RR, Tutsch KD, Verma AK, Douglas J, Pomplun M, Simsiman R, Wilding G. Low-dose difluoromethylornithine and polyamine levels in human prostate tissue Journal of the National Cancer Institute. 91: 1416-1417. PMID 10451448 DOI: 10.1093/Jnci/91.16.1416 |
0.453 |
|
| 1999 |
Ripple MO, Henry WF, Schwarze SR, Wilding G, Weindruch R. Effect of antioxidants on androgen-induced AP-1 and NF-kappaB DNA-binding activity in prostate carcinoma cells. Journal of the National Cancer Institute. 91: 1227-32. PMID 10413424 DOI: 10.1093/Jnci/91.14.1227 |
0.411 |
|
| 1999 |
Robins HI, Katschinski DM, Longo W, Grosen E, Wilding G, Gillis W, Kraemer C, Tiggelaar CL, Rushing D, Stewart JA, Spriggs D, Love R, Arzoomanian RZ, Feierabend C, Alberti D, et al. A pilot study of melphalan, tumor necrosis factor-α and 41.8 °C whole-body hyperthermia Cancer Chemotherapy and Pharmacology. 43: 409-414. PMID 10100597 DOI: 10.1007/S002800050915 |
0.402 |
|
| 1999 |
Church D, Zhang Y, Rago R, Wilding G. Efficacy of suramin against human prostate carcinoma DU145 xenografts in nude mice. Cancer Chemotherapy and Pharmacology. 43: 198-204. PMID 9923549 DOI: 10.1007/S002800050884 |
0.458 |
|
| 1999 |
Messing E, Manola J, Wilding G, Sarosdy M, Crawford D, Trump D. Immediate Hormonal Therapy Vs. Observation For Node Positive Prostate Cancer Following Radical Prostatectomy And Pelvic Lymphadenectomy: A Randomized Phase Iii Eastern Cooperative Oncology Group/Inter Group Trial The Journal of Urology. 175. DOI: 10.1097/00005392-199904010-00701 |
0.411 |
|
| 1998 |
Berlin JD, Alberti DB, Arzoomanian RZ, Feierabend CA, Simon KJ, Binger KA, Marnocha RM, Wilding G. A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors. Investigational New Drugs. 16: 325-330. PMID 10426665 DOI: 10.1023/A:1006242005837 |
0.44 |
|
| 1998 |
Pan HJ, Wilding G, Uno H, Inui S, Goldsmith L, Messing E, Chang C. Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques. Endocrine. 9: 39-43. PMID 9798729 DOI: 10.1385/Endo:9:1:39 |
0.381 |
|
| 1998 |
Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM, Bueschen AJ, Lowe BA. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer The New England Journal of Medicine. 339: 1036-1042. PMID 9761805 DOI: 10.1056/Nejm199810083391504 |
0.474 |
|
| 1998 |
Miyamoto H, Yeh S, Wilding G, Chang C. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells Proceedings of the National Academy of Sciences of the United States of America. 95: 7379-7384. PMID 9636157 DOI: 10.1073/Pnas.95.13.7379 |
0.425 |
|
| 1998 |
Berlin JD, Propert KJ, Trump D, Wilding G, Hudes G, Glick J, Burch P, Keller A, Loehrer P. 5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889). American Journal of Clinical Oncology. 21: 171-6. PMID 9537206 DOI: 10.1097/00000421-199804000-00016 |
0.505 |
|
| 1998 |
Berlin J, Stewart JA, Storer B, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Wilding G. Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy. Journal of Clinical Oncology. 16: 1142-1149. PMID 9508201 DOI: 10.1200/Jco.1998.16.3.1142 |
0.433 |
|
| 1998 |
Wilding G. Prostate Cancer Marc S. Ernstoff, John A. Heaney, Richard E. Peschel, eds. Malden (MA): Blackwell Science, Inc., 1998. 211 pp., illus. $75. ISBN 0-6320-43172 Journal of the National Cancer Institute. 90: 1904-1904. DOI: 10.1093/Jnci/90.24.1904 |
0.387 |
|
| 1997 |
Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun M, Mulcahy RT, Wilding G. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. Journal of the National Cancer Institute. 89: 1789-96. PMID 9392620 DOI: 10.1093/Jnci/89.23.1789 |
0.331 |
|
| 1997 |
Khorsand M, Lange J, Feun L, Clendeninn NJ, Collier M, Wilding G. Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder. Investigational New Drugs. 15: 157-63. PMID 9220296 DOI: 10.1023/A:1005860806635 |
0.42 |
|
| 1997 |
Jeffers L, Church D, Basu H, Marton L, Wilding G. Effects of the polyamine analogues BE-4-4-4-4, BE-3-7-3, and BE-3-3-3 on the proliferation of three prostate cancer cell lines. Cancer Chemotherapy and Pharmacology. 40: 172-179. PMID 9182840 DOI: 10.1007/S002800050643 |
0.458 |
|
| 1997 |
Berlin J, Tutsch KD, Hutson P, Cleary J, Rago RP, Arzoomanian RZ, Alberti D, Feierabend C, Wilding G. Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor. Journal of Clinical Oncology. 15: 781-789. PMID 9053505 DOI: 10.1200/Jco.1997.15.2.781 |
0.431 |
|
| 1997 |
Cleary JF, Arzoomanian R, Alberti D, Feierabend C, Storer B, Witt P, Carbone P, Wilding G. A phase I study of 5-fluorouracil, leucovorin and levamisole Cancer Chemotherapy and Pharmacology. 39: 300-306. PMID 9025770 DOI: 10.1007/S002800050576 |
0.431 |
|
| 1997 |
Mitchen J, Oberley T, Wilding G. Extended culturing of androgen-responsive human primary epithelial prostate cell isolates by continuous treatment with interstitial collagenase. The Prostate. 30: 7-19. PMID 9018330 DOI: 10.1002/(Sici)1097-0045(19970101)30:1<7::Aid-Pros2>3.0.Co;2-N |
0.389 |
|
| 1997 |
Robins HI, Rushing D, Kutz M, Tutsch KD, Tiggelaar CL, Paul D, Spriggs D, Kraemer C, Gillis W, Feierabend C, Arzoomanian RZ, Longo W, Alberti D, d'Oleire F, Qu RP, ... Wilding G, et al. Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 158-64. PMID 8996137 DOI: 10.1200/Jco.1997.15.1.158 |
0.453 |
|
| 1997 |
Ripple MO, Henry WF, Rago RP, Wilding G. Prooxidant-Antioxidant Shift Induced by Androgen Treatment of Human Prostate Carcinoma Cells Journal of the National Cancer Institute. 89: 40-48. PMID 8978405 DOI: 10.1093/Jnci/89.1.40 |
0.37 |
|
| 1997 |
Schulz C, Mehta M, Robins H, Badie B, Arzoomanian R, Simon K, Alberti D, Feierabend C, Kunugi K, Wilding G, Kinsella T. 9 Continuous 28 day iododeoxyuridine (IUdR) infusion and hyperfractionated accelerated radiotherapy (HART) for malignant glioma: A phase I clinical and thymidine replacement study International Journal of Radiation Oncology*Biology*Physics. 39: 139. DOI: 10.1016/S0360-3016(97)80567-6 |
0.351 |
|
| 1995 |
Mitchen J, Bletzinger D, Rago R, Wilding G. Use of a DNA microfluorometric assay to measure proliferative response of mink lung cells to purified TGFβ and to TGFβ activity found in prostate cell conditioned medium In Vitro Cellular & Developmental Biology – Animal. 31: 692-697. PMID 8564080 DOI: 10.1007/Bf02634090 |
0.307 |
|
| 1994 |
Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 12: 194-205. PMID 8270977 DOI: 10.1200/Jco.1994.12.1.194 |
0.328 |
|
| 1994 |
Berlin J, King AC, Tutsch K, Findlay JW, Kohler P, Collier M, Clendeninn NJ, Wilding G. A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma. Investigational New Drugs. 12: 137-41. PMID 7860231 DOI: 10.1007/Bf00874444 |
0.425 |
|
| 1993 |
Love RR, Carbone PP, Verma AK, Gilmore D, Carey P, Tutsch KD, Pomplun M, Wilding G. Randomized phase I chemoprevention dose-seeking study of α-difluoromethylornithine Journal of the National Cancer Institute. 85: 732-737. PMID 8478959 DOI: 10.1093/Jnci/85.9.732 |
0.443 |
|
| 1993 |
Hutson PR, Tutsch K, Springgs D, Christian M, Rago R, Mutch R, Wilding G. Evidence of an absorption phase after short intravenous suramin infusions. Cancer Chemotherapy and Pharmacology. 31: 495-499. PMID 8453691 DOI: 10.1007/Bf00685042 |
0.377 |
|
| 1993 |
Wilding G, Grindey G, Munshi N, Seitz D, Einhorn L. Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer Investigational New Drugs. 11: 203-205. PMID 8262732 DOI: 10.1007/Bf00874156 |
0.444 |
|
| 1993 |
Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer. 72: 2457-60. PMID 8104680 DOI: 10.1002/1097-0142(19931015)72:8<2457::AID-CNCR2820720825>3.0.CO;2-Z |
0.385 |
|
| 1993 |
Mitchen J, Rago R, Wilding G. Effects of suramin on the proliferation of primary epithelial cell cultures derived from normal, benign hyperplastic and cancerous human prostates. The Prostate. 22: 75-89. PMID 7678932 DOI: 10.1002/Pros.2990220110 |
0.367 |
|
| 1992 |
Dawson NA, Wilding G, Weiss RB, McLeod DG, Linehan WM, Frank JA, Jacob JL, Gelmann EP. A pilot trial of chemohormonal therapy for metastatic prostate carcinoma. Cancer. 69: 213-8. PMID 1727665 DOI: 10.1002/1097-0142(19920101)69:1<213::Aid-Cncr2820690135>3.0.Co;2-V |
0.455 |
|
| 1992 |
Bailey H, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Grem JL, Spriggs DR. A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions. Cancer Chemotherapy and Pharmacology. 30: 297-302. PMID 1643698 DOI: 10.1007/Bf00686299 |
0.399 |
|
| 1992 |
Dreicer R, Wilding G. Steroid hormone agonists and antagonists in the treatment of cancer. Cancer Investigation. 10: 27-41. PMID 1370912 DOI: 10.3109/07357909209032786 |
0.313 |
|
| 1991 |
Voeller HJ, Wilding G, Gelmann EP. v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells. Molecular Endocrinology (Baltimore, Md.). 5: 209-16. PMID 2038342 DOI: 10.1210/Mend-5-2-209 |
0.37 |
|
| 1991 |
Goldstein D, O’Leary M, Mitchen J, Borden EC, Wilding G. Effects of Interferon βser and Transforming Growth Factor β on Prostatic Cell Lines The Journal of Urology. 146: 1173-1177. PMID 1895445 DOI: 10.1016/S0022-5347(17)38034-5 |
0.353 |
|
| 1990 |
Wilding G, Gelmann EP, Freter CE. Phosphoinositide metabolism in human prostate cancer cells in vitro. The Prostate. 16: 15-27. PMID 2154736 DOI: 10.1002/Pros.2990160103 |
0.312 |
|
| 1989 |
Wilding G, Valverius E, Knabbe C, Gelmann EP. Role of transforming growth factor-alpha in human prostate cancer cell growth. The Prostate. 15: 1-12. PMID 2798227 DOI: 10.1002/Pros.2990150102 |
0.328 |
|
| 1989 |
Wilding G, Chen M, Gelmann EP. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. The Prostate. 14: 103-15. PMID 2710689 DOI: 10.1002/Pros.2990140204 |
0.422 |
|
| 1989 |
Wilding G, Zugmeier G, Knabbe C, Flanders K, Gelmann E. Differential effects of transforming growth factor beta on human prostate cancer cells in vitro. Molecular and Cellular Endocrinology. 62: 79-87. PMID 2545487 DOI: 10.1016/0303-7207(89)90115-9 |
0.313 |
|
| 1985 |
Wilding G, Caruso R, Lawrence TS, Ostchega Y, Ballintine EJ, Young RC, Ozols RF. Retinal toxicity after high-dose cisplatin therapy. Journal of Clinical Oncology. 3: 1683-1689. PMID 4067616 DOI: 10.1200/Jco.1985.3.12.1683 |
0.36 |
|
| Show low-probability matches. |
